Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Medhi Wangpaichitr

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Journal of Current Science and Technology|April 1, 2021
Perspective on the treatment of non-small cell lung cancer in the context of potential SARS-CoV-2 infection during the pandemicGeorge Theodoropoulos, Katerina Albanis, Medhi Wangpaichitr
Frontiers in Oncology|February 6, 2025
Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cellsIrene Kang, George Theodoropoulos, Medhi Wangpaichitr
Water Research|December 28, 2002
Evaluation of granular activated carbon technology for the removal of methyl tertiary butyl ether (MTBE) from drinking waterTom C Shih, Medhi Wangpaichitr, Mel Suffet
Journal of Personalized Medicine|February 25, 2025
Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer TherapyTaranatee Khan, Manojavan Nagarajan, Irene Kang, et al.
Reviews in Endocrine & Metabolic Disorders|November 26, 2024
The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disordersAndrew V Schally, Renzhi Cai, Xianyang Zhang, et al.
Angewandte Chemie (International Ed. in English)|December 13, 2017
A Kinetic Dearomatization Strategy for an Expedient Biomimetic Route to the Bielschowskysin SkeletonPaul Scesa, Medhi Wangpaichitr, Niramol Savaraj, et al.
Molecular Cancer Therapeutics|June 21, 2008
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell linesMedhi Wangpaichitr, Niramol Savaraj, Johnathan Maher, et al.
The Indian Journal of Radiology & Imaging|April 16, 2016
Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to knowShivank Bhatia, Keith Pereira, Prasoon Mohan, et al.
Molecular Cancer Therapeutics|February 20, 2007
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucoseJohnathan C Maher, Medhi Wangpaichitr, Niramol Savaraj, et al.
BMC Cancer|July 25, 2024
AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastomaMichael J Bickerdike, Imane Nafia, Alban Bessede, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Journal of Current Science and Technology|April 1, 2021
Perspective on the treatment of non-small cell lung cancer in the context of potential SARS-CoV-2 infection during the pandemicGeorge Theodoropoulos, Katerina Albanis, Medhi Wangpaichitr
Frontiers in Oncology|February 6, 2025
Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cellsIrene Kang, George Theodoropoulos, Medhi Wangpaichitr
Water Research|December 28, 2002
Evaluation of granular activated carbon technology for the removal of methyl tertiary butyl ether (MTBE) from drinking waterTom C Shih, Medhi Wangpaichitr, Mel Suffet
Journal of Personalized Medicine|February 25, 2025
Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer TherapyTaranatee Khan, Manojavan Nagarajan, Irene Kang, et al.
Reviews in Endocrine & Metabolic Disorders|November 26, 2024
The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disordersAndrew V Schally, Renzhi Cai, Xianyang Zhang, et al.
Angewandte Chemie (International Ed. in English)|December 13, 2017
A Kinetic Dearomatization Strategy for an Expedient Biomimetic Route to the Bielschowskysin SkeletonPaul Scesa, Medhi Wangpaichitr, Niramol Savaraj, et al.
Molecular Cancer Therapeutics|June 21, 2008
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell linesMedhi Wangpaichitr, Niramol Savaraj, Johnathan Maher, et al.
The Indian Journal of Radiology & Imaging|April 16, 2016
Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to knowShivank Bhatia, Keith Pereira, Prasoon Mohan, et al.
Molecular Cancer Therapeutics|February 20, 2007
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucoseJohnathan C Maher, Medhi Wangpaichitr, Niramol Savaraj, et al.
BMC Cancer|July 25, 2024
AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastomaMichael J Bickerdike, Imane Nafia, Alban Bessede, et al.
Pageof 6